Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomas Stulc

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|April 1, 2008
Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?Tomas Stulc, Richard Ceska
Diabetes Research and Clinical Practice|March 23, 2010
Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?Tomas Stulc, Aleksi Sedo
Neuro Endocrinology Letters|November 28, 2012
The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitusTomas Stulc, Richard Ceska, Iuri Marinov, et al.
International Journal of Cardiology|October 12, 2016
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvementMaciej Banach, Tomas Stulc, Ricardo Dent, et al.
The American Journal of Cardiology|September 3, 2004
Repeatability of noninvasive surrogates of endothelial functionJan Malik, Dan Wichterle, Tomas Haas, et al.
American Heart Journal|July 10, 2003
Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteineVojtech Melenovsky, Tomas Stulc, Viktor Kozich, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|April 1, 2008
Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?Tomas Stulc, Richard Ceska
Diabetes Research and Clinical Practice|March 23, 2010
Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?Tomas Stulc, Aleksi Sedo
Neuro Endocrinology Letters|November 28, 2012
The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitusTomas Stulc, Richard Ceska, Iuri Marinov, et al.
International Journal of Cardiology|October 12, 2016
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvementMaciej Banach, Tomas Stulc, Ricardo Dent, et al.
The American Journal of Cardiology|September 3, 2004
Repeatability of noninvasive surrogates of endothelial functionJan Malik, Dan Wichterle, Tomas Haas, et al.
American Heart Journal|July 10, 2003
Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteineVojtech Melenovsky, Tomas Stulc, Viktor Kozich, et al.
Pageof 1